PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer

The protein tyrosine phosphatase SHP2 activates oncogenic pathways downstream of most receptor tyrosine kinases (RTK) and has been implicated in various cancer types, including the highly aggressive subtype of triple-negative breast cancer (TNBC). Although allosteric inhibitors of SHP2 have been dev...

Descripción completa

Detalles Bibliográficos
Autores principales: Amante, Romain J., Jehanno, Charly, De Silva, Duvini, Coissieux, Marie-May, Ackerknecht, Markus, Romanet, Vincent, Sethi, Atul, Hamelin, Baptiste, Preca, Bogdan-Tiberius, Piscuoglio, Salvatore, Ng, Charlotte K. Y., Mohseni, Morvarid, Bentires-Alj, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256672/
https://www.ncbi.nlm.nih.gov/pubmed/37294349
http://dx.doi.org/10.1007/s10911-023-09539-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10256672/
https://www.ncbi.nlm.nih.gov/pubmed/37294349
http://dx.doi.org/10.1007/s10911-023-09539-9

Ejemplares similares